Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML/myeloproliferative neoplasm o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Verma, Dushyant, Kantarjian, Hagop, Strom, Sara S., Rios, Mary Beth, Jabbour, Elias, Quintas-Cardama, Alfonso, Verstovsek, Srdan, Ravandi, Farhad, O'Brien, Susan, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291487/
https://ncbi.nlm.nih.gov/pubmed/21846902
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-06-362889
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares